The earnings call reflected a positive outlook with significant advancements in clinical trials, financial stability, and preparation for regulatory approval. However, increased net loss, rising G&A expenses, and potential market competition are noted challenges.

Company Guidance

During the Mineralys Second Quarter 2025 Earnings Call, the company provided several key metrics and insights into its financial and clinical progress. Mineralys ended the quarter with $324.9 million in cash, cash equivalents, and investments, up from $198.2 million at the end of 2024, and anticipates these funds will support operations into 2027. Research and Development (R&D) expenses slightly decreased to $38.3 million from $39.3 million year-over-year, while General and Administrative (G&A) expenses increased to $8.5 million from $5.9 million. The company reported a net loss of $43.3 million for the quarter, up from $41 million in the same period the previous year. CEO Jon Congleton highlighted the success of lorundrostat, an aldosterone synthase inhibitor, in reducing systolic blood pressure in clinical trials and its potential market impact given the unmet need in treating hypertension and related comorbidities like chronic kidney disease (CKD) and obstructive sleep apnea (OSA). Surveys indicated 95% of clinicians would likely prescribe lorundrostat if approved, especially for patients with uncontrolled or resistant hypertension. Mineralys is preparing for a pre-NDA meeting with the FDA in the fourth quarter of 2025, aiming to bring lorundrostat to market as an innovative solution for significant unmet medical needs.

Clinical Trials Success and Publication

Mineralys announced pivotal data for their ASI, lorundrostat, from Launch-HTN and Advance-HTN trials, which were presented at leading conferences and published in prestigious journals.

Physician Survey Results

A survey of 300 cardiologists and primary care physicians indicated that 95% would likely prescribe lorundrostat broadly for patients with uncontrolled or resistant hypertension if approved.

Financial Position

Mineralys ended the quarter with $324.9 million in cash, cash equivalents, and investments, up from $198.2 million as of December 31, 2024, indicating financial stability to support operations into 2027.

Expansion of Medical Communications

Mineralys has expanded its medical communications team to support pre-launch readiness, indicating proactive steps towards commercialization.

Upcoming Regulatory Milestone

Mineralys has a pre-NDA meeting with the FDA scheduled for the fourth quarter of 2025, showing progress towards regulatory approval.

Mineralys Therapeutics, Inc. (MLYS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MLYS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.65 / -	-1.13	―	―	―
Aug 12, 2025	2025 (Q2)	-0.74 / -0.66	-0.83	20.48% (+0.17)	―
May 12, 2025	2025 (Q1)	-0.98 / -0.79	-0.7	-12.86% (-0.09)	―
Feb 12, 2025	2024 (Q4)	-1.08 / -0.98	-0.61	-60.66% (-0.37)	―
Nov 11, 2024	2024 (Q3)	-0.86 / -1.13	-0.57	-98.25% (-0.56)	―
Aug 13, 2024	2024 (Q2)	-0.70 / -0.83	-0.31	-167.74% (-0.52)	―
May 09, 2024	2024 (Q1)	-0.67 / -0.70	-0.51	-37.25% (-0.19)	―
Mar 21, 2024	2023 (Q4)	-0.82 / -0.61	-1.74	64.94% (+1.13)	―
Nov 07, 2023	2023 (Q3)	-0.76 / -0.57	-1.37	58.39% (+0.80)	―
Aug 07, 2023	2023 (Q2)	-0.72 / -0.31	-0.159	-94.97% (-0.15)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MLYS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$13.51	$13.56	+0.37%
May 12, 2025	$15.01	$15.19	+1.20%
Feb 12, 2025	$9.66	$10.63	+10.04%
Nov 11, 2024	$14.92	$13.38	-10.32%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Mineralys Therapeutics, Inc. (MLYS) report earnings?

Mineralys Therapeutics, Inc. (MLYS) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is Mineralys Therapeutics, Inc. (MLYS) earnings time?

Mineralys Therapeutics, Inc. (MLYS) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MLYS EPS forecast?

MLYS EPS forecast for the fiscal quarter 2025 (Q3) is -0.65.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing